Core A, the Administrative Core, will continue to provide organizational support for the leadership of the SPORE, facilitate communication among the component activities of the SPORE, serve as the home for pancreatic cancer SPORE advocate activities, and provide an organizational portal for collaborations outside the SPORE. Core A's functions are to: 1) Provide leadership and coordination between the Research Projects and Cores of the SPORE;2) Assure ongoing integration and participation of the Pancreatic Cancer SPORE in the activities of Mayo Clinic Cancer Center;3) Organize monthly meetings of the SPORE investigators;4) Organize yearly research retreats and meetings of the External Advisory Committee;5) Organize meetings of the SPORE Scientific Advisory Committee as needed;6) Organize monthly meetings of the SPORE Steering Committee;7) Provide administrative support to the Developmental Research Program;8) Provide administrative support to the Career Development Program;9) Facilitate investigator trips to the annual SPORE meetings in the mid-Atlantic region;10) Facilitate activities of the pancreatic cancer SPORE advocates;11) Prepare the yearly non-competing SPORE application;12) Serve as the administrative liaison between the Mayo Clinic SPORE and the NCI SPORE Program, other SPOREs, and collateral resources, such as PACGENE, PANC4, PanCAN, the Phase II Consortium, and the North Central Cancer Treatment Group;13) Maintain the Mayo Pancreatic Cancer SPORE websites that will be useful to investigators inside and outside the SPORE, as well as patients;14) Coordinate information and communication about SPORE-related research developments to and among the Mayo Clinic SPORE investigators, to the scientific community at large, and to the public. The Core leader, Dr. Petersen, will continue to direct Core A in close consultation with the Steering Committee so that maximum potential for translational objectives can continue to be achieved.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA102701-07
Application #
7878787
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
7
Fiscal Year
2009
Total Cost
$171,536
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Antwi, Samuel O; Bamlet, William R; Pedersen, Katrina S et al. (2018) Pancreatic Cancer Risk is Modulated by Inflammatory Potential of Diet and ABO Genotype: A Consortia-based Evaluation and Replication Study. Carcinogenesis :
Klein, Alison P; Wolpin, Brian M; Risch, Harvey A et al. (2018) Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nat Commun 9:556
Antwi, Samuel O; Petersen, Gloria M (2018) Leukocyte Telomere Length and Pancreatic Cancer Risk: Updated Epidemiologic Review. Pancreas 47:265-271
Penheiter, Alan R; Deelchand, Dinesh K; Kittelson, Emily et al. (2018) Identification of a pyruvate-to-lactate signature in pancreatic intraductal papillary mucinous neoplasms. Pancreatology 18:46-53
Nagpal, Sajan Jiv Singh; Bamlet, William R; Kudva, Yogish C et al. (2018) Comparison of Fasting Human Pancreatic Polypeptide Levels Among Patients With Pancreatic Ductal Adenocarcinoma, Chronic Pancreatitis, and Type 2 Diabetes Mellitus. Pancreas 47:738-741
Wolf, Susan M; Scholtes, Emily; Koenig, Barbara A et al. (2018) Pragmatic Tools for Sharing Genomic Research Results with the Relatives of Living and Deceased Research Participants. J Law Med Ethics 46:87-109
Tamura, Koji; Yu, Jun; Hata, Tatsuo et al. (2018) Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proc Natl Acad Sci U S A 115:4767-4772
Chaffee, Kari G; Oberg, Ann L; McWilliams, Robert R et al. (2018) Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history. Genet Med 20:119-127
Shroff, Rachna T; Hendifar, Andrew; McWilliams, Robert R et al. (2018) Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. JCO Precis Oncol 2018:
McWilliams, Robert R; Wieben, Eric D; Chaffee, Kari G et al. (2018) CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. Cancer Epidemiol Biomarkers Prev 27:1364-1370

Showing the most recent 10 out of 336 publications